2024 Speakers
 

 

Dennis Akkaya, Chief Commercial Officer, myTomorrows

Dennis Akkaya | Chief Commercial Officer | myTomorrows » speaking at Orphan Drug Congress

José Ángel Aibar, President, Dravet Syndrome Foundation

José Ángel Aibar | President | Dravet Syndrome Foundation » speaking at Orphan Drug Congress

Fabienne Bartoli, Inspector General, French National Authority for Health

Fabienne Bartoli | Inspector General | French National Authority for Health » speaking at Orphan Drug Congress

Anne-Sophie Chalandon, head of global public affairs, rare diseases and CGT policies, Sanofi

Anne-Sophie Chalandon | head of global public affairs, rare diseases and CGT policies | Sanofi » speaking at Orphan Drug Congress

Charlotte Chanson, Director Global Diagnostics, Orchard Therapeutics

Charlotte Chanson | Director Global Diagnostics | Orchard Therapeutics » speaking at Orphan Drug Congress

Rachel Cummings, Principal, DECISIVE CONSULTING LTD

Rachel Cummings | Principal | DECISIVE CONSULTING LTD » speaking at Orphan Drug Congress

Annabel De Maria, Chief Patient Officer, Alira Health

Annabel De Maria | Chief Patient Officer | Alira Health » speaking at Orphan Drug Congress

Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda

Toon Digneffe | Head, Public Affairs & Public Policy, Europe & Canada | Takeda » speaking at Orphan Drug Congress

Karen Facey, Senior Research Fellow, University of Edinburgh

Karen Facey | Senior Research Fellow | University of Edinburgh » speaking at Orphan Drug Congress

Pedro Franco, Senior Director, Head of Europe Global Regulatory and Scientific Policy, Merck

Pedro Franco | Senior Director, Head of Europe Global Regulatory and Scientific Policy | Merck » speaking at Orphan Drug Congress

Alicia Gil, Chief Executive Officer, Omakase Consulting

Alicia Gil | Chief Executive Officer | Omakase Consulting » speaking at Orphan Drug Congress

Josie Godfrey, Director, JG Zebra Consulting

Josie Godfrey | Director | JG Zebra Consulting » speaking at Orphan Drug Congress

Marcus Guardian, Chief Operating Officer, EUnetHTA

Marcus Guardian | Chief Operating Officer | EUnetHTA » speaking at Orphan Drug Congress

Alexandra Heumber Perry, Chief Executive Officer, Rare Diseases International

Alexandra Heumber Perry | Chief Executive Officer | Rare Diseases International » speaking at Orphan Drug Congress

Wills Hughes-Wilson, Chief Patient Access & Commercial Planning, Mereo Biopharma

Daria Julkowska, Assistant Director, Thematic Institute of Genetics, Genomics & Bioinformatics, EJP RD - IRDiRC

Daria Julkowska | Assistant Director, Thematic Institute of Genetics, Genomics & Bioinformatics | EJP RD - IRDiRC » speaking at Orphan Drug Congress

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam | Chief Executive Officer | EURORDIS » speaking at Orphan Drug Congress

Heidi Livingstone, Senior Public Involvement Adviser, National Institute for Health and Care Excellence

Heidi Livingstone | Senior Public Involvement Adviser | National Institute for Health and Care Excellence » speaking at Orphan Drug Congress

Karen Malone, Chief Executive Officer/Founder, GeneScape

Karen Malone | Chief Executive Officer/Founder | GeneScape » speaking at Orphan Drug Congress

Paolo Martini, Chief Scientific Officer Rare Diseases, Hematology and External R&D, Moderna, Inc.

Paolo Martini | Chief Scientific Officer Rare Diseases, Hematology and External R&D | Moderna, Inc. » speaking at Orphan Drug Congress

Lucy Mckay, Chief Executive Officer, Medics4RareDiseases

Lucy Mckay | Chief Executive Officer | Medics4RareDiseases » speaking at Orphan Drug Congress

Dinesh Mistry, executive director- regulatory strategy, Fortrea

Dinesh Mistry | executive director- regulatory strategy | Fortrea » speaking at Orphan Drug Congress

Andrew Mumford, Chief Executive Officer, Initiate Consultancy

Andrew Mumford | Chief Executive Officer | Initiate Consultancy » speaking at Orphan Drug Congress

Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

Alexander Natz | Director General | EUCOPE - European Confederation of Pharmaceutical Entrepreneurs » speaking at Orphan Drug Congress

Daniel O'Connor, Director, Regulatory Policy & Early Access, ABPI

Daniel O'Connor | Director, Regulatory Policy & Early Access | ABPI » speaking at Orphan Drug Congress

Samantha Parker, Chief Patient Officer, Innoskel

Samantha Parker | Chief Patient Officer | Innoskel » speaking at Orphan Drug Congress

Enrico Piccinini, Head of Europe Rare Diseases, Chiesi Group

Enrico Piccinini | Head of Europe Rare Diseases | Chiesi Group » speaking at Orphan Drug Congress

Jessica Roberts, Director, Pharmacometrics, Allucent

Jessica Roberts | Director, Pharmacometrics | Allucent » speaking at Orphan Drug Congress

Kacper Rucinski, Executive Committee Member, SMA Europe

Kacper Rucinski | Executive Committee Member | SMA Europe » speaking at Orphan Drug Congress

Christopher Rudolf, Founder and Chief Executive Officer, volv global

Christopher Rudolf | Founder and Chief Executive Officer | volv global » speaking at Orphan Drug Congress

Adrien Samson, Healthcare Policy and Public Affairs Senior Manager, EuropaBio

Adrien Samson | Healthcare Policy and Public Affairs Senior Manager | EuropaBio » speaking at Orphan Drug Congress

Maurizio Scarpa, Director, Coordinating Center For Rare Diseases, MetabERN

Maurizio Scarpa | Director, Coordinating Center For Rare Diseases | MetabERN » speaking at Orphan Drug Congress

Sophie Schmitz, Managing Partner, Partners4Access

Sophie Schmitz | Managing Partner | Partners4Access » speaking at Orphan Drug Congress

Nick Sireau, Chair and Chief Executive Officer, AKU Society

Nick Sireau | Chair and Chief Executive Officer | AKU Society » speaking at Orphan Drug Congress

Claire Skentelbery, Director General, EuropaBio

Claire Skentelbery | Director General | EuropaBio » speaking at Orphan Drug Congress

Rachel Smith, Executive Director, Rare Disease Center of Excellence, Parexel

Rachel Smith | Executive Director, Rare Disease Center of Excellence | Parexel » speaking at Orphan Drug Congress

Violeta Stoyanova-Beninska, Chair of Committee for Orphan Medicinal Products, Medicines Evaluation Board

Violeta Stoyanova-Beninska | Chair of Committee for Orphan Medicinal Products | Medicines Evaluation Board » speaking at Orphan Drug Congress

Rick Thompson, Chief Executive Officer, Beacon

Rick Thompson | Chief Executive Officer | Beacon » speaking at Orphan Drug Congress

Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Fipra International

Sheela Upadhyaya | Life Science Advisor in Rare Diseases & Special Advisor | Fipra International » speaking at Orphan Drug Congress

Anton Ussi, Operations Director, EATRIS ERIC

Anton Ussi | Operations Director | EATRIS ERIC » speaking at Orphan Drug Congress

Leon van Wouwe, Clinical Innovation Director, volv global

Leon van Wouwe | Clinical Innovation Director | volv global » speaking at Orphan Drug Congress

Mary Wang, Programme Director, Rare Diseases International

Mary Wang | Programme Director | Rare Diseases International » speaking at Orphan Drug Congress

Laura Webber, Chief Operating Officer, HealthLumen

Laura Webber | Chief Operating Officer | HealthLumen » speaking at Orphan Drug Congress

Nicky Wisener, Vice-President of Business Development, Clinigen Group

Nicky Wisener | Vice-President of Business Development | Clinigen Group » speaking at Orphan Drug Congress

Durhane Wong-Rieger, President, Chief Executive Officer & Chair, Canadian Organisation for Rare Diseases & Rare Diseases International

Durhane Wong-Rieger | President, Chief Executive Officer & Chair | Canadian Organisation for Rare Diseases & Rare Diseases International » speaking at Orphan Drug Congress

Martine Zimmermann, Senior Vice President, Head of Regulatory, R&D Quality, Ipsen

Martine Zimmermann | Senior Vice President, Head of Regulatory, R&D Quality | Ipsen » speaking at Orphan Drug Congress